Latest News and Press Releases

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.

The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal...

OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...

OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as...

OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today positive results from a pilot clinical trial...

OCEANSIDE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) together with The Right to Try Foundation announced filing of a...

OCEANSIDE, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- NetworkWire – Therapeutics Solutions International, Inc., (OTC Markets: TSOI) reported today positive animal data demonstrating synergy at...

— Part B of the study, a subsequent extension of the optimal dose from Part A, to enroll 10 first-recurrent GBM patients— Initial immunologic data from Part B expected around year-end 2019— Expanded...